Next Article in Journal
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation
Next Article in Special Issue
Improving the Management of Endometrial Cancer Patients through the Use of Liquid Biopsy Analyses: A Case Report
Previous Article in Journal
Alcohol Dependence Induces CRF Sensitivity in Female Central Amygdala GABA Synapses
Previous Article in Special Issue
Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 14
10.3390/ijms23147843
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers

Int. J. Mol. Sci. 2022, 23(14), 7843; https://doi.org/10.3390/ijms23147843
by Sridevi Addanki 1,2, Salyna Meas 2,3, Vanessa Nicole Sarli 2,3, Balraj Singh 2,3 and Anthony Lucci 2,3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(14), 7843; https://doi.org/10.3390/ijms23147843
Submission received: 23 June 2022 / Revised: 14 July 2022 / Accepted: 15 July 2022 / Published: 16 July 2022
(This article belongs to the Special Issue Liquid Biopsies in Oncology)

Round 1

Reviewer 1 Report

The authors present many data on the detection fo CTCs by the cell search sytem. This relies on EpCAM detection. Hovewer, EpCAM is down-regulated during EMT. The authors should discuss this problem as it migth lead to a lower detection number of CTCs.

Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, von Ahsen O. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 2012 May 16;12:178. doi: 10.1186/1471-2407-12-178. PMID: 22591372; PMCID: PMC3502112.

The above paper corroborates earlier experimental findings (EGP2 = EpCAM):

 

Jojović M, Adam E, Zangemeister-Wittke U, Schumacher U. Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice. Histochem J. 1998 Oct;30(10):723-9. doi: 10.1023/a:1003486630314. PMID: 9873999.

Author Response

Thank you for bringing up this critical caveat of the CellSearch system. We briefly mentioned it earlier in the manuscript; we now included a small paragraph discussing the insensitivity of the CellSearch Immuno-magnetic system to detect changes in the epithelial marker. Please find it in the section “Drawbacks of existing liquid biopsy approaches” lines 495-511.

Reviewer 2 Report

This is a detailed review of current knowledge and use of circulating tumour biomarkers in breast cancer.

The major strengths of this review include in-depth description of previous studies that have analysed the use of circulating tumour biomarkers in prognostication with some comments on personalised medicine. 

There remains a large gap in the scientific literature with regards to early diagnosis of patients with breast cancer using these techniques, which the review highlights appropriately.

 

The tables present a summary of key results from papers cited in this review.

 

Spelling/Grammar

Line 278: in the heading, 'breast' is spelt incorrectly

Line 553: 'investigating' is spelt incorrectly

Author Response

Thank you for the comments; we made the edits to the manuscript and ran it through spellcheck.

Back to TopTop